Interest of Botulinum Toxin in the Treatment of Temporomandibular Disorder
Author(s): Saida El Khayati 1*, Jalal Hamama1, Karim El Khatib 1, Amal El yamani 2
Temporomandibular Disorders (TMD) refer to a group of debilitating masticatory conditions that are often associated with
considerable morbidity and a reduction in a person’s quality of life. Approximately 44% of the population are affected, but
only a quarter of them seek professional help.
The aim of this review was to critically investigate and assess the evidence relating to the use and efficacy of Botulinum
Toxin (BTX) in the management of temporomandibular joint disorders and masticatory myofascial pain.
A comprehensive search was conducted of PubMed, Scopus, Embase, and Cochrane central, to find relevant studies from the
last 30 years up to the end of April 2021, using the following Mesh terms: Botulinum Toxin, Temporomandibular Joint
Despite the demonstrated benefits, a consensus on the therapeutic benefit of BTX in the management of TMD, bruxism and
masticatory myofascial pain is lacking. Further randomized controlled trials with larger sample sizes, minimal bias and
longer follow-up periods are now needed.